Drug Policy:
Tavalisse™ (fostamatinib)

I. PURPOSE
To define and describe the accepted indications for Tavalisse (fostamatinib) usage in the treatment of cancer, including FDA approved indications, and off-label indications.

New Century Health (NCH) is responsible for processing all medication requests from network ordering providers. Medications not authorized by NCH may be deemed as not approvable and therefore not reimbursable.

The use of this drug must be supported by one of the following: FDA approved product labeling, CMS-approved compendia, National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) clinical guidelines, or peer-reviewed literature that meets the requirements of the CMS Medicare Benefit Policy Manual Chapter 15.

II. INDICATIONS FOR USE/INCLUSION CRITERIA

A. PREFERRED MEDICATION GUIDANCE FOR INITIAL REQUEST:
   1. When health plan Medicaid coverage provisions—including any applicable PDLs (Preferred Drug Lists)—conflict with the coverage provisions in this drug policy, health plan Medicaid coverage provisions take precedence per the Preferred Drug Guidelines OR
   2. When health plan Exchange coverage provisions—including any applicable PDLs (Preferred Drug Lists)—conflict with the coverage provisions in this drug policy, health plan Exchange coverage provisions take precedence per the Preferred Drug Guidelines OR
   3. For Health Plans that utilize NCH UM Oncology Clinical Policies as the initial clinical criteria, the Preferred Drug Guidelines shall follow NCH L1 Pathways
(http://pathways.newcenturyhealth.com/) when applicable, otherwise shall follow NCH drug policies AND

4. Continuation requests of previously approved, non-preferred medication are not subject to this provision AND

5. When applicable, generic alternatives are preferred over brand-name drugs AND

6. When there is a documented drug shortage, disease progression, contraindication, or confirmed intolerance to a Preferred drug/regimen, per NCH Policy and Pathway, the available alternative product may be used if deemed medically appropriate and the indication is listed in a standard reference compendia or accepted peer review literature. For a list of current drug shortages, please refer to FDA drug shortage website in the reference section.

B. Immune Thrombocytopenic Purpura (ITP)

1. Tavalisse (fostamatinib) may be used as a single agent, or in combination with one concomitant ITP medication (limited to one of the following: corticosteroids < 20 mg prednisone/equivalent daily, azathioprine, or danazol) when the following criteria have been satisfied:
   a. The member has relapsed/refractory chronic ITP AND
   b. For initial request: There has been an insufficient response (defined by failure of platelet count to increase and stay above 30 x 10^9/L) to prior therapies including corticosteroids, IVIG, splenectomy/Rituxan, and/or a Thrombopoietin Receptor Agonist (romiplostim, eltrombopag or avatrombopag) AND a platelet count ≤ 30 x 10^9/L prior to start of therapy OR
   c. For continuation request: The member did not achieve a rise in Platelet counts or the member continues to experience significant bleeding any time during treatment with Tavalisse (fostamatinib).

III. EXCLUSION CRITERIA

A. Dosing exceeds single dose limit of Tavalisse (fostamatinib) 150 mg.

B. Treatment exceeds the maximum limit of 60 (100 mg or 150 mg) tablets/month.

C. Investigational use of Tavalisse (fostamatinib) with an off-label indication that is not sufficient in evidence or is not generally accepted by the medical community. Sufficient evidence that is not supported by CMS recognized compendia or acceptable peer reviewed literature is defined as any of the following:
   1. Whether the clinical characteristics of the patient and the cancer are adequately represented in the published evidence.
   2. Whether the administered chemotherapy/biologic therapy/immune therapy/targeted therapy/other oncologic therapy regimen is adequately represented in the published evidence.
   3. Whether the reported study outcomes represent clinically meaningful outcomes experienced by patients. Generally, the definition of Clinically Meaningful outcomes are those recommended by ASCO, e.g., Hazard Ratio of < 0.80 and the recommended survival benefit for OS and PFS should be at least 3 months.
   4. Whether the experimental design, in light of the drugs and conditions under investigation, is appropriate to address the investigative question. (For example, in some clinical studies, it may be unnecessary or not feasible to use randomization, double blind trials, placebos, or crossover).
5. That non-randomized clinical trials with a significant number of subjects may be a basis for supportive clinical evidence for determining accepted uses of drugs.
6. That case reports are generally considered uncontrolled and anecdotal information and do not provide adequate supportive clinical evidence for determining accepted uses of drugs.
7. That abstracts (including meeting abstracts) without the full article from the approved peer-reviewed journals lack supporting clinical evidence for determining accepted uses of drugs.

### IV. MEDICATION MANAGEMENT

A. Please refer to the FDA label/package insert for details regarding these topics.

### V. APPROVAL AUTHORITY

A. Review – Utilization Management Department
B. Final Approval – Utilization Management Committee

### VI. ATTACHMENTS

A. None

### VII. REFERENCES